{"title":"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer","authors":"J. Zabell","doi":"10.1093/MED/9780190655341.003.0015","DOIUrl":null,"url":null,"abstract":"This chapter summarizes the findings of landmark TAX 327 trial in men with castrate-refractory prostate cancer who received either docetaxel (weekly or every 3 weeks) or mitoxantrone (every 3 weeks). The study found improved overall survival, better quality of life, and similar side effects in men treated with docetaxel.","PeriodicalId":435097,"journal":{"name":"50 Studies Every Urologist Should Know","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"50 Studies Every Urologist Should Know","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/MED/9780190655341.003.0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 21
Abstract
This chapter summarizes the findings of landmark TAX 327 trial in men with castrate-refractory prostate cancer who received either docetaxel (weekly or every 3 weeks) or mitoxantrone (every 3 weeks). The study found improved overall survival, better quality of life, and similar side effects in men treated with docetaxel.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
